Frontiers in Oncology (Jun 2022)
18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: Location and HPV Specific Parameters for Potential Treatment Individualization
- Sebastian Zschaeck,
- Sebastian Zschaeck,
- Sebastian Zschaeck,
- Sebastian Zschaeck,
- Sebastian Zschaeck,
- Julian Weingärtner,
- Julian Weingärtner,
- Elia Lombardo,
- Sebastian Marschner,
- Sebastian Marschner,
- Marina Hajiyianni,
- Marcus Beck,
- Daniel Zips,
- Daniel Zips,
- Daniel Zips,
- Yimin Li,
- Qin Lin,
- Holger Amthauer,
- Esther G. C. Troost,
- Esther G. C. Troost,
- Esther G. C. Troost,
- Esther G. C. Troost,
- Esther G. C. Troost,
- Esther G. C. Troost,
- Esther G. C. Troost,
- Jörg van den Hoff,
- Volker Budach,
- Jörg Kotzerke,
- Jörg Kotzerke,
- Jörg Kotzerke,
- Konstantinos Ferentinos,
- Efstratios Karagiannis,
- David Kaul,
- Vincent Gregoire,
- Adrien Holzgreve,
- Nathalie L. Albert,
- Pavel Nikulin,
- Michael Bachmann,
- Klaus Kopka,
- Mechthild Krause,
- Mechthild Krause,
- Mechthild Krause,
- Mechthild Krause,
- Mechthild Krause,
- Mechthild Krause,
- Mechthild Krause,
- Michael Baumann,
- Michael Baumann,
- Michael Baumann,
- Michael Baumann,
- Michael Baumann,
- Joanna Kazmierska,
- Joanna Kazmierska,
- Paulina Cegla,
- Witold Cholewinski,
- Witold Cholewinski,
- Iosif Strouthos,
- Klaus Zöphel,
- Klaus Zöphel,
- Klaus Zöphel,
- Klaus Zöphel,
- Ewa Majchrzak,
- Guillaume Landry,
- Claus Belka,
- Claus Belka,
- Carmen Stromberger,
- Frank Hofheinz
Affiliations
- Sebastian Zschaeck
- Department of Radiation Oncology, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- Sebastian Zschaeck
- Berlin Institute of Health (BIH), Berlin, Germany
- Sebastian Zschaeck
- Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- Sebastian Zschaeck
- German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ) Heidelberg, Germany, Germany
- Sebastian Zschaeck
- OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany
- Julian Weingärtner
- Department of Radiation Oncology, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- Julian Weingärtner
- Berlin Institute of Health (BIH), Berlin, Germany
- Elia Lombardo
- Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany
- Sebastian Marschner
- Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany
- Sebastian Marschner
- German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
- Marina Hajiyianni
- Department of Radiation Oncology, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- Marcus Beck
- Department of Radiation Oncology, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- Daniel Zips
- Department of Radiation Oncology, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- Daniel Zips
- German Cancer Consortium (DKTK), Partner Site Tübingen, and German Cancer Research Center (DKFZ) Heidelberg, Germany, Germany
- Daniel Zips
- Department of Radiation Oncology, University Hospital and Medical Faculty, Eberhard Karls University Tübingen, Tübingen, Germany
- Yimin Li
- 0Department of Radiation Oncology, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Xiamen, China
- Qin Lin
- 0Department of Radiation Oncology, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Xiamen, China
- Holger Amthauer
- 1Department of Nuclear Medicine, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- Esther G. C. Troost
- Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- Esther G. C. Troost
- German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ) Heidelberg, Germany, Germany
- Esther G. C. Troost
- OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany
- Esther G. C. Troost
- 2Institute of Radiooncology – OncoRay, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany
- Esther G. C. Troost
- 3National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany
- Esther G. C. Troost
- 4Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- Esther G. C. Troost
- 5 Helmholtz Association/Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany
- Jörg van den Hoff
- 6Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
- Volker Budach
- Department of Radiation Oncology, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- Jörg Kotzerke
- German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ) Heidelberg, Germany, Germany
- Jörg Kotzerke
- OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany
- Jörg Kotzerke
- 7Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden, Germany
- Konstantinos Ferentinos
- 8Department of Radiation Oncology, German Oncology Center, European University Cyprus, Limassol, Cyprus
- Efstratios Karagiannis
- 8Department of Radiation Oncology, German Oncology Center, European University Cyprus, Limassol, Cyprus
- David Kaul
- Department of Radiation Oncology, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- Vincent Gregoire
- 9Radiation Oncology Department, Leon Bérard Cancer Center, Lyon, France
- Adrien Holzgreve
- 0Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
- Nathalie L. Albert
- 0Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
- Pavel Nikulin
- 6Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
- Michael Bachmann
- 6Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
- Klaus Kopka
- 6Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
- Mechthild Krause
- Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- Mechthild Krause
- German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ) Heidelberg, Germany, Germany
- Mechthild Krause
- OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany
- Mechthild Krause
- 2Institute of Radiooncology – OncoRay, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany
- Mechthild Krause
- 3National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany
- Mechthild Krause
- 4Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- Mechthild Krause
- 5 Helmholtz Association/Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany
- Michael Baumann
- Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- Michael Baumann
- German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ) Heidelberg, Germany, Germany
- Michael Baumann
- OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany
- Michael Baumann
- 2Institute of Radiooncology – OncoRay, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany
- Michael Baumann
- 1German Cancer Research Center (DKFZ), Heidelberg, Germany
- Joanna Kazmierska
- 2Electroradiology Department, University of Medical Sciences, Poznan, Poland
- Joanna Kazmierska
- 3Radiotherapy Department II, Greater Poland Cancer Centre, Poznan, Poland
- Paulina Cegla
- 4Department of Nuclear Medicine, Greater Poland Cancer Centre, Poznan, Poland
- Witold Cholewinski
- 2Electroradiology Department, University of Medical Sciences, Poznan, Poland
- Witold Cholewinski
- 4Department of Nuclear Medicine, Greater Poland Cancer Centre, Poznan, Poland
- Iosif Strouthos
- 8Department of Radiation Oncology, German Oncology Center, European University Cyprus, Limassol, Cyprus
- Klaus Zöphel
- German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ) Heidelberg, Germany, Germany
- Klaus Zöphel
- OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany
- Klaus Zöphel
- 7Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden, Germany
- Klaus Zöphel
- 5Department of Nuclear Medicine, Klinikum Chemnitz gGmbH, Chemnitz, Germany
- Ewa Majchrzak
- 6Department of Head and Neck Surgery, Poznan University of Medical Sciences, Greater Poland Cancer Centre, Poznan, Poland
- Guillaume Landry
- Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany
- Claus Belka
- Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany
- Claus Belka
- German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
- Carmen Stromberger
- Department of Radiation Oncology, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- Frank Hofheinz
- 6Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
- DOI
- https://doi.org/10.3389/fonc.2022.870319
- Journal volume & issue
-
Vol. 12
Abstract
Purpose18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is utilized for staging and treatment planning of head and neck squamous cell carcinomas (HNSCC). Some older publications on the prognostic relevance showed inconclusive results, most probably due to small study sizes. This study evaluates the prognostic and potentially predictive value of FDG-PET in a large multi-center analysis.MethodsOriginal analysis of individual FDG-PET and patient data from 16 international centers (8 institutional datasets, 8 public repositories) with 1104 patients. All patients received curative intent radiotherapy/chemoradiation (CRT) and pre-treatment FDG-PET imaging. Primary tumors were semi-automatically delineated for calculation of SUVmax, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG). Cox regression analyses were performed for event-free survival (EFS), overall survival (OS), loco-regional control (LRC) and freedom from distant metastases (FFDM).ResultsFDG-PET parameters were associated with patient outcome in the whole cohort regarding clinical endpoints (EFS, OS, LRC, FFDM), in uni- and multivariate Cox regression analyses. Several previously published cut-off values were successfully validated. Subgroup analyses identified tumor- and human papillomavirus (HPV) specific parameters. In HPV positive oropharynx cancer (OPC) SUVmax was well suited to identify patients with excellent LRC for organ preservation. Patients with SUVmax of 14 or less were unlikely to develop loco-regional recurrence after definitive CRT. In contrast FDG PET parameters deliver only limited prognostic information in laryngeal cancer.ConclusionFDG-PET parameters bear considerable prognostic value in HNSCC and potential predictive value in subgroups of patients, especially regarding treatment de-intensification and organ-preservation. The potential predictive value needs further validation in appropriate control groups. Further research on advanced imaging approaches including radiomics or artificial intelligence methods should implement the identified cut-off values as benchmark routine imaging parameters.
Keywords
- head and neck squamous cell carcinoma (HNSCC)
- fluorodeoxyglucose positron emission tomography (FDG PET)
- radiotherapy
- metabolic tumor volume (MTV)
- standardized uptake value (SUV)